Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: A cross-sectional multicentre study

International Journal of Clinical Practice

Volumn 67, Issue 12, 2013, Pages 1294-1301

  Corhay, J L ^a   Vincken, W ^b   Schlesser, M ^c   Bossuyt, P ^d   Imschoot, J ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^d Medical Department   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYGEN; THEOPHYLLINE DERIVATIVE;

AGE; AGED; ARTICLE; BELGIUM; CACHEXIA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LUNG EMPHYSEMA; LUXEMBOURG; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; OBSERVATIONAL STUDY; OCCUPATIONAL HAZARD; PREVALENCE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; VITAL CAPACITY;

ACUTE DISEASE; AGED; BRONCHITIS, CHRONIC; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RISK FACTORS; SMOKING; VITAL CAPACITY;

EID: 84888052047     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12248     Document Type: Article

References (28)

1. Agusti A, Calverley P, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122-35.
2. From the Global Strategy for the Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. 2013. http://www.goldcopd.org/ (accessed July 2013).
3. Lu M, Yao W, Zhong N, et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology 2010; 15: 1072-8.
4. Montes de Oca M, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012; 40: 28-36.
5. Kanner RE, Anthonisen NR, Connett JE,. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-64. (Pubitemid 32778199)
6. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761-7.
7. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140: 626-33.
8. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
9. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL,. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.
10. Burgel P-R, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-82.
11. Prescott E, Lange P, Vestbo J,. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-8.
12. Pelkonen M, Notkola I-L, Nissinen A, Tukiainen H, Koskela H,. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129-37. (Pubitemid 44583744)
13. Ekberg-Aronsson M, Pehrsson K, Nilsson J-A, Nilsson PM, Löfdahl C-G,. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98.
14. Vestbo J, Prescott E, Lange P,. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-5. (Pubitemid 26141336)
15. Snoeck-Stroband JB, Lapperre TS, Gosman MME, et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31: 70-7.
16. Kim V, Criner GJ,. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 228-37.
17. Dompeling E, Van Schayck CP, Molema J, Folgering H, Van Grunsven PM, Van Weel C,. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992; 5: 945-52.
18. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J,. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80. (Pubitemid 28112338)
19. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77-121.
20. Burgel P-R,. Chronic cough and sputum production: a clinical COPD phenotype? Eur Respir J 2012; 40: 4-6.
21. Montnémery P, Adelroth E, Heuman K, et al. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med 1998; 92: 1337-45. (Pubitemid 29002771)
22. Meteran H, Thomsen SF, Harmsen L, Kyvik KO, Skytthe A, Backer V,. Risk of chronic bronchitis in twin pairs discordant for smoking. Lung 2012; 190: 557-61.
23. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-85.
24. Portillo K, Martinez-Rivera C, Ruiz-Manzano J,. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract 2013; 67: 558-65.
25. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
26. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
27. Nannini LJ, Lasserson TJ, Poole P,. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD006829. doi: 10.1002/14651858.CD006829.pub2.
28. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA,. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1418-22.